GlobeNewsWire
06 Mar 2026, 13:30 UTC · 29w ago
Verdict
Headline takes no side. We score SLDB +0.60 across four claims — strongly bullish.
+0.60strongly bullish
More positive than 75% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Solid Biosciences will present an update on the INSPIRE DUCHENNE Phase 1/2 study of SGT-003 at the 2026 MDA Clinical & Scientific Conference.
More positive than 93% of claims this week
The company will present data showing a positive preliminary safety and liver toxicity profile for SGT-003.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 78% of claims this week
Solid Biosciences will present efficacy and safety data for SGT-212, its investigational gene therapy for Friedreich’s ataxia.
More positive than 64% of claims this week
The company will present data claiming SGT-003 demonstrates high cardiac tropism and improves muscle integrity in Duchenne muscular dystrophy.
More positive than 64% of claims this week
Which stocks this story touches
More positive than 75% of ticker scores this week
The company is announcing multiple presentations of positive preliminary safety and clinical findings for its gene therapy candidates at a major scientific conference.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
1h ago
+30.6%
Price agrees with the score
$7.33 vs $5.61 close before publication (Mar 5) · not market-adjusted
SLDB chart →
